157 related articles for article (PubMed ID: 35905950)
1. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer.
Li T; Song R; Wang J; Zhang J; Cai H; He H; Hu W; Yu D; Wang C; Pan Q; Peng M; Ren H; Zhu P
Int J Infect Dis; 2022 Sep; 122():874-884. PubMed ID: 35905950
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
[TBL] [Abstract][Full Text] [Related]
3. Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer.
Song R; Liu L; Pan Q; Liu J; Tan J; Deng J; Deng Q; Lin Z; Chen M; Peng M; Ren H; Ming J
Front Immunol; 2022; 13():1028246. PubMed ID: 36353624
[TBL] [Abstract][Full Text] [Related]
4. Immune responses to inactivated COVID-19 vaccine were decreased in Chinese patients with chronic respiratory diseases.
Yang L; Xu L; Guo Q; Deng B; Hong Y; Wang L; Wang Y; Jiang D; Ren H
Int J Med Sci; 2023; 20(6):737-748. PubMed ID: 37213672
[No Abstract] [Full Text] [Related]
5. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV.
Ao L; Lu T; Cao Y; Chen Z; Wang Y; Li Z; Ren X; Xu P; Peng M; Chen M; Zhang G; Xiang D; Cai D; Hu P; Shi X; Zhang D; Ren H
Emerg Microbes Infect; 2022 Dec; 11(1):1126-1134. PubMed ID: 35369854
[TBL] [Abstract][Full Text] [Related]
6. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer.
Han S; Yang Y; Wang T; Song R; Hu D; Peng M; Lin Z; Deng Q; Ren H; Ming J
Front Public Health; 2023; 11():1086872. PubMed ID: 36817926
[TBL] [Abstract][Full Text] [Related]
8. Impaired antibody responses were observed in patients with type 2 diabetes mellitus after receiving the inactivated COVID-19 vaccines.
Xiang F; Long B; He J; Cheng F; Zhang S; Liu Q; Chen Z; Li H; Chen M; Peng M; Yin W; Liu D; Ren H
Virol J; 2023 Feb; 20(1):22. PubMed ID: 36750902
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
[TBL] [Abstract][Full Text] [Related]
10. Cellular and Humoral Responses to Recombinant and Inactivated SARS-CoV-2 Vaccines in CKD Patients: An Observational Study.
Zhang S; He J; Tang B; Zhou Q; Hu Y; Yu Y; Chen J; Liu Y; Li C; Ren H; Liao X
J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769873
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
[TBL] [Abstract][Full Text] [Related]
12. The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients.
Yang L; Xiang F; Wang D; Guo Q; Deng B; Jiang D; Ren H
Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):503-512. PubMed ID: 36849838
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of inactivated SARS-CoV-2 vaccine in haemodialysis patients: a prospective cohort study.
Puspitasari M; Sattwika PD; Rahari DS; Wijaya W; Hidayat ARP; Kertia N; Purwanto B; Thobari JA
Sci Rep; 2023 Jul; 13(1):11557. PubMed ID: 37463975
[TBL] [Abstract][Full Text] [Related]
14. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
[TBL] [Abstract][Full Text] [Related]
15. Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study.
Lu T; Chen Z; Cao Y; Ao L; Li Z; Gu X; Ren X; Wang Y; Zhang G; Xiang D; Chen M; Cai D; Hu P; Zhang D; Peng M; Shi X; Ren H
J Med Virol; 2023 Apr; 95(4):e28730. PubMed ID: 37185852
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
17. Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection.
Zhou Y; Chen Z; He Y; Peng X; Chang Y; Tan A; Li H; Cai D; Hu P; Chen M; Peng M; Xu H; Ren H
Front Cell Infect Microbiol; 2023; 13():1201101. PubMed ID: 37457966
[TBL] [Abstract][Full Text] [Related]
18. Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination.
Liang B; Xiang T; Wang H; Li Z; Quan X; Feng X; Li S; Lu S; Fan L; Xu L; Wang T; Wang X; Zhu B; Wang J; Yang D; Liu J; Zheng X
Front Immunol; 2022; 13():966098. PubMed ID: 35979361
[TBL] [Abstract][Full Text] [Related]
19. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
Omma A; Batirel A; Aydin M; Yilmaz Karadag F; Erden A; Kucuksahin O; Armagan B; Güven SC; Karakas O; Gokdemir S; Altunal LN; Buber AA; Gemcioglu E; Zengin O; Inan O; Sahiner ES; Korukluoglu G; Sezer Z; Ozdarendeli A; Kara A; Ates I
Hum Vaccin Immunother; 2022 Nov; 18(6):2122503. PubMed ID: 36315843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
